<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9(6)</volume><submitter>Shen C</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Transient receptor potential cation channel subfamily V (TRPV) play an essential in cancer initiation, progression, and treatment. TRPV expression alteration are shown relate to multiple cancers prognosis and treatment of cancers but are less-studied in pan-cancer. In this study, we characterize the clinical prediction value of TRPV at pan-cancer level.&lt;h4>Methods&lt;/h4>Several databases were used to examine the transcript expression difference in tumor vs. normal tissue, copy-number variant (CNV) and single nucleotide polymorphisms (SNP) mutation of each TRPV members in pan-cancer, including The Cancer Genome Atlas (TCGA) and cBioPortal. We performed K-M survival curve and univariate Cox regression analyses to identify survival and prognosis value of TRPV. CellMiner were </pubmed_abstract><journal>Heliyon</journal><pagination>e16897</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10279839</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.</pubmed_title><pmcid>PMC10279839</pmcid><pubmed_authors>Fan Z</pubmed_authors><pubmed_authors>Shen C</pubmed_authors><pubmed_authors>Lin Y</pubmed_authors><pubmed_authors>Chen H</pubmed_authors><pubmed_authors>Li K</pubmed_authors><pubmed_authors>Suo Y</pubmed_authors><pubmed_authors>Wu Z</pubmed_authors><pubmed_authors>Huang S</pubmed_authors><pubmed_authors>Fu C</pubmed_authors><pubmed_authors>Li Z</pubmed_authors><pubmed_authors>Zhang Z</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Hu H</pubmed_authors><pubmed_authors>Yang S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.</name><description>&lt;h4>Background&lt;/h4>Transient receptor potential cation channel subfamily V (TRPV) play an essential in cancer initiation, progression, and treatment. TRPV expression alteration are shown relate to multiple cancers prognosis and treatment of cancers but are less-studied in pan-cancer. In this study, we characterize the clinical prediction value of TRPV at pan-cancer level.&lt;h4>Methods&lt;/h4>Several databases were used to examine the transcript expression difference in tumor vs. normal tissue, copy-number variant (CNV) and single nucleotide polymorphisms (SNP) mutation of each TRPV members in pan-cancer, including The Cancer Genome Atlas (TCGA) and cBioPortal. We performed K-M survival curve and univariate Cox regression analyses to identify survival and prognosis value of TRPV. CellMiner were </description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jun</publication><modification>2026-04-07T13:32:57.811Z</modification><creation>2025-02-19T04:31:05.618Z</creation></dates><accession>S-EPMC10279839</accession><cross_references><pubmed>37346342</pubmed><doi>10.1016/j.heliyon.2023.e16897</doi></cross_references></HashMap>